This company is delisted or no longer publicly traded. The analysis below is archived and will not be updated.

Esperion Therapeutics, Inc. ESPR

Updated: 9 Aug 2026

NASDAQ | Biotech | Cardiovascular biopharmaceuticals
Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Cardiovascular biopharmaceuticals
We're already tracking Esperion Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On July 13, 2026, Esperion Therapeutics completed its acquisition by investment firm ARCHIMED. Under the agreement, stockholders received $3.16 per share in cash plus one contingent value right per share, and the company was delisted from NASDAQ.

What Firelda Watch includes for Esperion Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Esperion Therapeutics, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Boozt AB (publ)
BOOZT
HOLD
Vitrolife AB (publ)
VITR
HOLD
Bioarctic
BIOA B
BUY
Lagercrantz Group
LAGR B
NEUTRAL
Tetra Tech, Inc.
TTEK
HOLD

Biotech

More companies in this sector

Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.